The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

A product recall initiated by Cipla on 12/22/2020 has been changed from wholesale level to retail level.

Product: Esomeprazole Magnesium for Delayed Release Oral Suspension 10 mg, 20 mg, and 40 mg,

Affected lot numbers: Lots KA00415, KA00416, KA00411, KA00412, KA00460, KA00461, KA00413 and KA00414.

The start date of distribution was 04/07/2020. The product is labeled for and marketed by Cipla USA Inc. bearing the NDC Numbers 69097-527-34, 69097-528-34, and 69097-529-34.